Literature DB >> 24623469

Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody-associated vasculitis: a study of 439 cases in a single Chinese center.

Zhi-Ying Li1, Dong-Yuan Chang, Ming-Hui Zhao, Min Chen.   

Abstract

OBJECTIVE: Treatment resistance and relapse in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) are major challenges for physicians. The aim of this study was to assess the risk factors for treatment resistance and relapse in a single-center cohort of Chinese patients with AAV.
METHODS: Four hundred thirty-nine consecutive patients with AAV were recruited for inclusion in this study. The value of various clinical and pathologic parameters for the prediction of treatment resistance and relapse was analyzed.
RESULTS: Treatment resistance occurred in 47 (10.7%) of 439 patients and was independently associated with a higher serum creatinine level (odds ratio [OR] 1.087, 95% confidence interval [95% CI] 1.001-1.180, P = 0.047), a higher erythrocyte sedimentation rate (OR 1.009, 95% CI 1.001-1.018, P = 0.025), therapy with corticosteroids plus cyclophosphamide (OR 0.115, 95% CI 0.051-0.256, P = 0.000), and the presence of muscle pain (OR 0.249, 95% CI 0.083-0.747, P = 0.013). Relapse occurred in 128 (32.7%) of 392 patients in whom remission was achieved and was independently associated with lung involvement (hazard ratio [HR] 1.768, 95% CI 1.088-2.872, P = 0.021) and a lower serum creatinine level (HR 0.925, 95% CI 0.872-0.981, P = 0.009).
CONCLUSION: In Chinese patients with AAV, lung involvement and lower serum creatinine levels were independently associated with an increased risk of relapse. Elevated serum creatinine levels were associated with treatment resistance.
Copyright © 2014 by the American College of Rheumatology.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24623469     DOI: 10.1002/art.38621

Source DB:  PubMed          Journal:  Arthritis Rheumatol        ISSN: 2326-5191            Impact factor:   10.995


  28 in total

1.  Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type.

Authors:  Sebastian Unizony; Miguel Villarreal; Eli M Miloslavsky; Na Lu; Peter A Merkel; Robert Spiera; Philip Seo; Carol A Langford; Gary S Hoffman; Cg M Kallenberg; E William St Clair; David Ikle; Nadia K Tchao; Linna Ding; Paul Brunetta; Hyon K Choi; Paul A Monach; Fernando Fervenza; John H Stone; Ulrich Specks
Journal:  Ann Rheum Dis       Date:  2015-11-30       Impact factor: 19.103

2.  Risk factors for treatment resistance and relapse of Chinese patients with MPO-ANCA-associated vasculitis.

Authors:  Li Huang; Chanjuan Shen; Yong Zhong; Joshua D Ooi; Ya-Ou Zhou; Jin-Biao Chen; Ting Wu; Ting Meng; Zhou Xiao; Wei Lin; Xiang Ao; Xiangcheng Xiao; Qiaoling Zhou; Ping Xiao
Journal:  Clin Exp Med       Date:  2020-02-20       Impact factor: 3.984

3.  Distinction between MPO-ANCA and PR3-ANCA-associated glomerulonephritis in Chinese patients: a retrospective single-center study.

Authors:  Yan Hong; Pengxian Shi; Xia Liu; Liu Yang; Kang Li; Feng Xu; Shaoshan Liang; Zhengzhao Liu; Haitao Zhang; Yinghua Chen; Weixin Hu
Journal:  Clin Rheumatol       Date:  2019-02-08       Impact factor: 2.980

4.  Clinicopathologic characteristics and outcomes of renal thrombotic microangiopathy in anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis.

Authors:  Su-Fang Chen; Huan Wang; Yi-Min Huang; Zhi-Ying Li; Su-Xia Wang; Feng Yu; Ming-Hui Zhao; Min Chen
Journal:  Clin J Am Soc Nephrol       Date:  2015-03-06       Impact factor: 8.237

Review 5.  [S1 guidelines Diagnostics and treatment of ANCA-associated vasculitis].

Authors:  Jan Henrik Schirmer; Peer M Aries; Kirsten de Groot; Bernhard Hellmich; Julia U Holle; Christian Kneitz; Ina Kötter; Peter Lamprecht; Ulf Müller-Ladner; Eva Reinhold-Keller; Christof Specker; Michael Zänker; Frank Moosig
Journal:  Z Rheumatol       Date:  2017-11       Impact factor: 1.372

6.  Neutrophil-Related Gene Expression and Low-Density Granulocytes Associated With Disease Activity and Response to Treatment in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.

Authors:  Peter C Grayson; Carmelo Carmona-Rivera; Lijing Xu; Noha Lim; Zhong Gao; Adam L Asare; Ulrich Specks; John H Stone; Philip Seo; Robert F Spiera; Carol A Langford; Gary S Hoffman; Cees G M Kallenberg; E William St Clair; Nadia K Tchao; Steven R Ytterberg; Deborah J Phippard; Peter A Merkel; Mariana J Kaplan; Paul A Monach
Journal:  Arthritis Rheumatol       Date:  2015-07       Impact factor: 10.995

Review 7.  The Prevalence and Management of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis in China.

Authors:  Zhi-Ying Li; Tian-Tian Ma; Min Chen; Ming-Hui Zhao
Journal:  Kidney Dis (Basel)       Date:  2015-12-09

8.  The epidemiology of antineutrophil cytoplasmic antibody-associated vasculitis in northwestern Turkey.

Authors:  Ömer Nuri Pamuk; Salim Dönmez; Gökçe Büşra Calayır; Gülsüm Emel Pamuk
Journal:  Clin Rheumatol       Date:  2016-03-18       Impact factor: 2.980

9.  Severe Infections following Rituximab Treatment in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.

Authors:  Zhi-Ying Li; Min Chen; Ming-Hui Zhao
Journal:  Kidney Dis (Basel)       Date:  2020-08-23

10.  Clinical features of IgA nephropathy with serum ANCA positivity: a retrospective case-control study.

Authors:  Ya-Zi Yang; Su-Fang Shi; Yu-Qing Chen; Min Chen; Yi-He Yang; Xin-Fang Xie; Rong Zou; Ji-Cheng Lv; Li-Jun Liu; Hong Zhang
Journal:  Clin Kidney J       Date:  2015-08-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.